Market Cap 10.38B
Revenue (ttm) 4.07B
Net Income (ttm) 560.12M
EPS (ttm) N/A
PE Ratio 38.49
Forward PE 8.11
Profit Margin 13.77%
Debt to Equity Ratio 1.35
Volume 1,110,300
Avg Vol 1,299,310
Day's Range N/A - N/A
Shares Out 60.77M
Stochastic %K 75%
Beta 0.27
Analysts Strong Sell
Price Target $218.87

Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymp...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 634 7800
Address:
Waterloo Exchange, Fifth Floor Waterloo Road Dublin 4, Dublin, Ireland
JuggernautRaider
JuggernautRaider Jan. 16 at 4:27 PM
Happy to. IQVIA & Symphony & Komodo are the three pharma industry leaders in sales (demand) data. biopharma data in the US is TERRIBLE given the market structure, number of different payers, et al. Often when a product is launched - particularly oral products like $TNXP Tonmya, $INCY Jakafi, $KPTI Xpovio, and even some infusion products like $JAZZ ’s Zepzelca they will block the distributors from selling the data. Usually 10-30% is not captured, but up to 60-95% can be if the pharma company only uses a few distributors & specialty pharamcies. Now this is demand or sales data - for claims data, which shows much more information (with the patient data hidden). However I doubt Tonix is doing that as it can be expensive (you have to pay them to do this - they know how valuable the data is to stock analyst & competitors). I’m hopeful we’ll see the first quarter of demand data from Tonmya soon - which will be its first month (during the holidays!) 😬 Almost to 10K shares long 💎 💪
3 · Reply
JuggernautRaider
JuggernautRaider Jan. 16 at 4:15 PM
$TNXP we should see Symphony Or Komodo sales data for Tonmya soon… assuming Tonix isn’t using contracts with ira distributors to block it like $JAZZ and $KPTI and $INCY do 📊 this is a little trade secret for you all 🤫 get these shares while they’re cheap, I’m buying more ☘️ GLBB 🚀
1 · Reply
Quantumup
Quantumup Jan. 16 at 2:30 PM
Piper Sandler⬆️ $AXSM's PT to $223 from $148, reiterated at an Overweight and said, 'Remaining Bullish' $ACAD $JAZZ OTSKY HLUBF HLBBF JNJ TEVA Here's more of what Piper Sandler had to say: https://x.com/Quantumup1/status/2012169826177806564?s=20
0 · Reply
mpap_
mpap_ Jan. 15 at 11:15 PM
$RCKT Good chances of approval for Kresladi. Solid Data. Real need for this ultra rare disease. If approved would also get a PRV, recently $JAZZ sold one for $200M . Extends runway without dilution. PT is $8-10 upon approval as may de=risk the company for the foreseeable future. If not approved then the stock will tank, runway just with cash only until 2027 Q2. As Martin Shkreli said once in his livestream, you don't want to have to beg for approval, you want to go in and have the FDA high five you and say "great job guys, making the USA proud". I think this fits this treatment and disease.
1 · Reply
Chaka1647
Chaka1647 Jan. 14 at 9:05 PM
$FBIOP Bought more today. Risk / Reward is just outstanding. Especially since seeing that $JAZZ sold PRv for such a high number
1 · Reply
JFDI
JFDI Jan. 14 at 7:25 PM
$JAZZ wowza!
0 · Reply
Bigsky007
Bigsky007 Jan. 13 at 8:56 PM
$EVTV $IXHL $JAZZ $LLY $RMD Well BB 23 you picked a good day for a recap. I needed a refresher course.
1 · Reply
BullButter23
BullButter23 Jan. 13 at 8:43 PM
$EVTV Still Bullish but I jumped out a little early to move my profits into $IXHL . They’ve created a first of its kind pill (IHL-42X) to treat Sleep Apnea, which affects over 1 billion people worldwide. It’s been proven to have 83% efficacy with ZERO side effects and has been FDA fast-tracked for Phase 3. IXHL cancelled 350 million warrants and announced the option to exercise a $20M buyback. IHXL has $70M in cash on hand, which is plenty to get this drug through phase 3 and they very recently accelerated vesting its board members. Marijuana was just rescheduled (III) for pharmaceutical purposes, and IXHL owns 19 related patents with 23 more pending, which makes it the largest patented medical marijuana portfolio in the world. Its stock is currently undervalued by 6X and is due for rerate. AGM is scheduled for Thursday. Lots of speculation about a merger or buyout. Potential suitors are $RMD, $LLY, $JAZZ, etc.. with RMD having the most to lose. (CPAP machine maker.) Go check em out
0 · Reply
IN0V8
IN0V8 Jan. 12 at 6:46 PM
$JAZZ Buy Needham raises target price to $235 from $210 Truist Securities raises target to $230 from $220
0 · Reply
prismmarketview
prismmarketview Jan. 12 at 6:35 PM
JAZZ Pharamaceuticals $JAZZ & Boehringer Partner to Advance Zanidatamab Strategy https://prismmarketview.com/jazz-boehringer-partner-to-advance-zanidatamab-strategy/
0 · Reply
Latest News on JAZZ
Jazz Pharmaceuticals to Participate in Upcoming Investor Events

Dec 17, 2025, 4:15 PM EST - 4 weeks ago

Jazz Pharmaceuticals to Participate in Upcoming Investor Events


Trials, Sales Wins Sends Jazz Pharmaceuticals Higher

Dec 5, 2025, 7:12 AM EST - 6 weeks ago

Trials, Sales Wins Sends Jazz Pharmaceuticals Higher


Jazz Pharmaceuticals Appoints Ted W. Love, M.D.

Oct 28, 2025, 4:05 PM EDT - 2 months ago

Jazz Pharmaceuticals Appoints Ted W. Love, M.D.


US FDA approves Jazz Pharma's therapy for lung cancer

Oct 2, 2025, 3:37 PM EDT - 3 months ago

US FDA approves Jazz Pharma's therapy for lung cancer


US FDA approves Jazz Pharma's drug for rare brain tumor

Aug 6, 2025, 3:00 PM EDT - 5 months ago

US FDA approves Jazz Pharma's drug for rare brain tumor


Is JAZZ Stock Undervalued At $110?

Jul 7, 2025, 10:05 AM EDT - 6 months ago

Is JAZZ Stock Undervalued At $110?


Jazz Pharmaceuticals: One Step Forward, One Back

May 21, 2025, 4:58 AM EDT - 8 months ago

Jazz Pharmaceuticals: One Step Forward, One Back


JuggernautRaider
JuggernautRaider Jan. 16 at 4:27 PM
Happy to. IQVIA & Symphony & Komodo are the three pharma industry leaders in sales (demand) data. biopharma data in the US is TERRIBLE given the market structure, number of different payers, et al. Often when a product is launched - particularly oral products like $TNXP Tonmya, $INCY Jakafi, $KPTI Xpovio, and even some infusion products like $JAZZ ’s Zepzelca they will block the distributors from selling the data. Usually 10-30% is not captured, but up to 60-95% can be if the pharma company only uses a few distributors & specialty pharamcies. Now this is demand or sales data - for claims data, which shows much more information (with the patient data hidden). However I doubt Tonix is doing that as it can be expensive (you have to pay them to do this - they know how valuable the data is to stock analyst & competitors). I’m hopeful we’ll see the first quarter of demand data from Tonmya soon - which will be its first month (during the holidays!) 😬 Almost to 10K shares long 💎 💪
3 · Reply
JuggernautRaider
JuggernautRaider Jan. 16 at 4:15 PM
$TNXP we should see Symphony Or Komodo sales data for Tonmya soon… assuming Tonix isn’t using contracts with ira distributors to block it like $JAZZ and $KPTI and $INCY do 📊 this is a little trade secret for you all 🤫 get these shares while they’re cheap, I’m buying more ☘️ GLBB 🚀
1 · Reply
Quantumup
Quantumup Jan. 16 at 2:30 PM
Piper Sandler⬆️ $AXSM's PT to $223 from $148, reiterated at an Overweight and said, 'Remaining Bullish' $ACAD $JAZZ OTSKY HLUBF HLBBF JNJ TEVA Here's more of what Piper Sandler had to say: https://x.com/Quantumup1/status/2012169826177806564?s=20
0 · Reply
mpap_
mpap_ Jan. 15 at 11:15 PM
$RCKT Good chances of approval for Kresladi. Solid Data. Real need for this ultra rare disease. If approved would also get a PRV, recently $JAZZ sold one for $200M . Extends runway without dilution. PT is $8-10 upon approval as may de=risk the company for the foreseeable future. If not approved then the stock will tank, runway just with cash only until 2027 Q2. As Martin Shkreli said once in his livestream, you don't want to have to beg for approval, you want to go in and have the FDA high five you and say "great job guys, making the USA proud". I think this fits this treatment and disease.
1 · Reply
Chaka1647
Chaka1647 Jan. 14 at 9:05 PM
$FBIOP Bought more today. Risk / Reward is just outstanding. Especially since seeing that $JAZZ sold PRv for such a high number
1 · Reply
JFDI
JFDI Jan. 14 at 7:25 PM
$JAZZ wowza!
0 · Reply
Bigsky007
Bigsky007 Jan. 13 at 8:56 PM
$EVTV $IXHL $JAZZ $LLY $RMD Well BB 23 you picked a good day for a recap. I needed a refresher course.
1 · Reply
BullButter23
BullButter23 Jan. 13 at 8:43 PM
$EVTV Still Bullish but I jumped out a little early to move my profits into $IXHL . They’ve created a first of its kind pill (IHL-42X) to treat Sleep Apnea, which affects over 1 billion people worldwide. It’s been proven to have 83% efficacy with ZERO side effects and has been FDA fast-tracked for Phase 3. IXHL cancelled 350 million warrants and announced the option to exercise a $20M buyback. IHXL has $70M in cash on hand, which is plenty to get this drug through phase 3 and they very recently accelerated vesting its board members. Marijuana was just rescheduled (III) for pharmaceutical purposes, and IXHL owns 19 related patents with 23 more pending, which makes it the largest patented medical marijuana portfolio in the world. Its stock is currently undervalued by 6X and is due for rerate. AGM is scheduled for Thursday. Lots of speculation about a merger or buyout. Potential suitors are $RMD, $LLY, $JAZZ, etc.. with RMD having the most to lose. (CPAP machine maker.) Go check em out
0 · Reply
IN0V8
IN0V8 Jan. 12 at 6:46 PM
$JAZZ Buy Needham raises target price to $235 from $210 Truist Securities raises target to $230 from $220
0 · Reply
prismmarketview
prismmarketview Jan. 12 at 6:35 PM
JAZZ Pharamaceuticals $JAZZ & Boehringer Partner to Advance Zanidatamab Strategy https://prismmarketview.com/jazz-boehringer-partner-to-advance-zanidatamab-strategy/
0 · Reply
erevnon
erevnon Jan. 12 at 12:03 PM
Needham maintains Jazz Pharmaceuticals $JAZZ at Buy and raises the price target from $210 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
anachartanalyst
anachartanalyst Jan. 12 at 10:02 AM
$JAZZ https://anachart.com/wp-content/uploads/ana_temp/1768212074_soc-img.jpg
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jan. 9 at 2:50 PM
$ACRV Going LONG in 2026. Huge breakthrough in cancer research here. All that matters to me. Seen $JAZZ Pharma hit $3.19 then $299 dollars in a month years back. #HOLDING
1 · Reply
catacal_
catacal_ Jan. 9 at 6:37 AM
$JAZZ CATALYST: 2026 ASCO Gastrointestinal Cancers Symposium is happening on Fri. Jan. 9 at 9:30 AM. Don't get blindsided by upcoming catalysts. Track this catalyst and more at: https://www.catacal.com/catalyst/2026-asco-gastrointestinal-cancers-symposium $SPY $QQQ
0 · Reply
catacal_
catacal_ Jan. 9 at 5:55 AM
$JAZZ CATALYST: American Society of Clinical Oncology Gastrointestinal Cancers Symposium is happening on Fri. Jan. 9 at 9:30 AM. Don't get blindsided by upcoming catalysts. Track this catalyst and more at: https://www.catacal.com/catalyst/american-society-of-clinical-oncology-gastrointestinal-cancers-symposium $SPY $QQQ
0 · Reply
theflynews
theflynews Jan. 8 at 11:34 PM
Closing Bell Movers: AXT Inc. slips after cutting Q4 revenue guidance - $JAZZ - https://thefly.com/permalinks/entry.php/JAZZid4267708?17679
0 · Reply
G101SPM
G101SPM Jan. 7 at 8:17 PM
#SHOWTIME American Society of Clinical Oncology Gastrointestinal Cancers Symposium (January 8-10) Scheduled to appear: $ACTU, $CATX, $JAZZ, $ZYME
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jan. 7 at 4:34 PM
Attached is a history of the XBI's closing share price in the week leading up to the annual JPM H/C conference, the week of & the week after JPM. Last year the markets were closed the Thursday before JPM to mourn the loss of President Jimmy Carter. Days on tope are calendar days versus JPM start date. The markets are closed the Monday after JP Morgan for Martin Luther King Jr. Day. Of course what's happened the last few years is no indication of what will happen this year. Still, the change in the XBI is literally up then down year after year for the last 6 years. If history repeats itself, and we have no idea if it will but if history does repeat itself, the XBI will close down the week after JP Morgan this year. We are betting INCY will announce a $SNDX acquisition next week. If we are wrong as we usually are, then it is likely SNDX will trade lower after JPM if (that's the 2nd big if) the XBI trades lower. Same with $IOVA $JAZZ This is not investment advice $XBI $IBB
1 · Reply
prismmarketview
prismmarketview Jan. 7 at 1:58 PM
Jazz Pharmaceuticals (Nasdaq: $JAZZ) reported positive early clinical data for its HER2‑targeted antibody Ziihera (zanidatamab‑hrii) in combination therapies, showing strong efficacy with a manageable safety profile. https://prismmarketview.com/jazz-pharma-reports-positive-data-for-zanidatamab-combination-therapies-in-early-clinical-studies/
0 · Reply
Quantumup
Quantumup Jan. 7 at 12:55 PM
BTIG⬆️its PT on $DRUG to $147 from $72 and reiterated at a Buy rating. $HLUBF / HLBBF $UCBJY $JAZZ $PRAX STOK - BIIB SLNO RYTM AARD Here's what BTIG had to say in its note to investors: https://x.com/Quantumup1/status/2008883937020354987?s=20
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Jan. 6 at 9:51 PM
0 · Reply
Shane_Crawford
Shane_Crawford Jan. 6 at 8:44 PM
$JAZZ $LUDG Sharp little article. https://pubco-ludg.tiiny.site/
0 · Reply